Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.55 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919287 | 1.00 | DNM1 (0.55) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| Acetic Acid SCHEMBL29280656 | 0.92 | BCHE (0.54) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL893963 | 0.88 | BCHE (0.63) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| Hydrochloric Acid SCHEMBL28487274 | 0.84 | DNM1 (0.51) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL11300746 | 0.83 | ALDH1A1 (0.49) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL2919648 | 0.83 | GAA (0.60) | DNM1ALDH1A1MEN1KMT2A | |
| SCHEMBL3079282 | 0.82 | DNM1 (0.57) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL10533348 | 0.82 | DNM1 (0.57) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL14015727 | 0.82 | DNM1 (0.57) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL28508915 | 0.82 | DNM1 (0.50) | DNM1BCHEALDH1A1ANPEPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023036140-A1 | 3CLPRO PROTEASE INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-03-16 | — | — | WO | disclosed |
| EP-2166847-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2166847-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013046211-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL) PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013046211-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL) PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-04-04 | — | — | WO | disclosed |
| US-8293721-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARPE & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293721-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARPE & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293721-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARPE & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
| EP-2166847-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156718-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156718-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | DNM1 3268/4885BCHE 1091/4885ALDH1A1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.